{"id":"W4385897815","doi":"10.1093/oncolo/oyad197","title":"Outcomes of Combination Platinum-Doublet Chemotherapy and Anti-PD(L)-1 Blockade in KRASG12C-Mutant Non-Small Cell Lung Cancer","year":2023,"lang":"en","type":"article","venue":"The Oncologist","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Canadian Institutes of Health Research; Legend Biotech; EMD Serono; Genentech; Revolution Medicines; Flatiron Health; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; Sanofi; Bristol-Myers Squibb; Eli Lilly and Company; AstraZeneca; Amgen; Pfizer; National Center for Advancing Translational Sciences; LUNGevity Foundation","keywords":"Medicine; Immunotherapy; Internal medicine; Oncology; Pembrolizumab; Lung cancer; Response Evaluation Criteria in Solid Tumors; Chemotherapy; Cancer; Progressive disease","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005261677,0.000141648,0.0003817966,0.0001140541,0.00006245809,0.0000124979,0.0001292532,0.0001007584,0.00009429965],"category_scores_gemma":[0.00001969433,0.00009068381,0.00006653666,0.0004291576,0.0002074722,0.00003099958,0.00004182346,0.0001579653,0.000003989642],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001478854,"about_ca_system_score_gemma":0.0001358345,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001583519,"about_ca_topic_score_gemma":0.000454084,"domain_scores_codex":[0.9990724,0.00004380105,0.000312876,0.000187999,0.0001592292,0.0002237164],"domain_scores_gemma":[0.9993671,0.000176065,0.0001596772,0.0002254693,0.00003866137,0.00003305636],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.001146393,0.0003068038,0.795787,0.0002160918,0.000164563,0.00003001872,0.002290266,0.00003267888,0.1888362,0.00003818771,0.001985207,0.009166539],"study_design_scores_gemma":[0.008217159,0.0002714499,0.948275,0.0001132659,0.00006209833,0.000006421794,0.0005808782,0.001196572,0.03953943,0.00004003266,0.001570832,0.0001268579],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9888659,0.0005859778,0.000009587389,0.007912502,0.0002011195,0.0006936842,0.00001706699,0.00004527356,0.001668861],"genre_scores_gemma":[0.9954183,0.002263561,0.00005524312,0.0007340692,0.00004084124,0.00005870599,0.00001290091,0.00001959469,0.001396861],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.152488,"threshold_uncertainty_score":0.3697979,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02275108764639615,"score_gpt":0.3174268817104426,"score_spread":0.2946757940640465,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}